A share price of VYNE Therapeutics Inc [VYNE] is currently trading at $0.37, up 15.23%. An important factor to consider is whether the stock is rising or falling in short-term value. The VYNE shares have gain 12.21% over the last week, with a monthly amount glided 19.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
VYNE Therapeutics Inc [NASDAQ: VYNE] stock has seen the most recent analyst activity on July 31, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, BTIG Research started tracking the stock with Buy rating on November 18, 2024, and set its price target to $8.
VYNE Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.28 and $4.30. Currently, Wall Street analysts expect the stock to reach $5.75 within the next 12 months. VYNE Therapeutics Inc [NASDAQ: VYNE] shares were valued at $0.37 at the most recent close of the market. An investor can expect a potential return of 1454.05% based on the average VYNE price forecast.
Analyzing the VYNE fundamentals
Trailing Twelve Months sales for VYNE Therapeutics Inc [NASDAQ:VYNE] were 0.48M which represents -65.15% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -89.5%, Pretax Profit Margin comes in at -80.92%, and Net Profit Margin reading is -80.98%. To continue investigating profitability, this company’s Return on Assets is posted at -0.86, Equity is -0.78 and Total Capital is -1.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3363 points at the first support level, and at 0.3004 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3919, and for the 2nd resistance point, it is at 0.4116.
Ratios To Look Out For
To put it in perspective, the Current Ratio for VYNE Therapeutics Inc [NASDAQ:VYNE] is 7.60. On the other hand, the Quick Ratio is 7.60, and the Cash Ratio is 3.78. Considering the valuation of this stock, the price to sales ratio is 19.75, the price to book ratio is 0.19.
Transactions by insiders
Recent insider trading involved LEPORE PATRICK G, Director, that happened on Jan 15 ’25 when 15000.0 shares were purchased.
